Northern Trust’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $933K | Buy |
133,841
+4,986
| +4% | +$38.7K | ﹤0.01% | 3373 |
|
|
2025
Q4 | $910K | Buy |
128,855
+12,513
| +11% | +$96.6K | ﹤0.01% | 3425 |
|
|
2025
Q3 | $868K | Sell |
116,342
-26,987
| -19% | -$205K | ﹤0.01% | 3459 |
|
|
2025
Q2 | $1.05M | Buy |
143,329
+35,319
| +33% | +$308K | ﹤0.01% | 3359 |
|
|
2025
Q1 | $834K | Buy |
108,010
+4,628
| +4% | +$50.8K | ﹤0.01% | 3358 |
|
|
2024
Q4 | $1.25M | Buy |
103,382
+8,624
| +9% | +$110K | ﹤0.01% | 3285 |
|
|
2024
Q3 | $1.19M | Buy |
94,758
+62,058
| +190% | +$800K | ﹤0.01% | 3280 |
|
|
2024
Q2 | $390K | Buy |
32,700
+8,632
| +36% | +$118K | ﹤0.01% | 3601 |
|
|
2024
Q1 | $421K | Sell |
24,068
-546
| -2% | -$9.84K | ﹤0.01% | 3618 |
|
|
2023
Q4 | $632K | Buy |
24,614
+18,853
| +327% | +$267K | ﹤0.01% | 3460 |
|
|
2023
Q3 | $41.7K | Hold |
5,761
| – | – | ﹤0.01% | 4208 |
|
|
2023
Q2 | $30.4K | Hold |
5,761
| – | – | ﹤0.01% | 4326 |
|
|
2023
Q1 | $17.9K | Sell |
5,761
-5,761
| -50% | -$21.9K | ﹤0.01% | 4466 |
|
|
2022
Q4 | $45.6K | Hold |
11,522
| – | – | ﹤0.01% | 4301 |
|
|
2022
Q3 | $44K | Buy |
11,522
+251
| +2% | +$3.19K | ﹤0.01% | 4356 |
|
|
2022
Q2 | $150K | Buy |
11,271
+113
| +1% | +$751 | ﹤0.01% | 4027 |
|
|
2022
Q1 | $55K | Sell |
11,158
-2,463
| -18% | -$12.2K | ﹤0.01% | 4510 |
|
|
2021
Q4 | $93K | Sell |
13,621
-162
| -1% | -$2.77K | ﹤0.01% | 4446 |
|
|
2021
Q3 | $425K | Sell |
13,783
-476
| -3% | -$15.7K | ﹤0.01% | 3825 |
|
|
2021
Q2 | $463K | Sell |
14,259
-30,572
| -68% | -$1.05M | ﹤0.01% | 3742 |
|
|
2021
Q1 | $1.69M | Buy |
44,831
+3,808
| +9% | +$174K | ﹤0.01% | 3328 |
|
|
2020
Q4 | $1.94M | Sell |
41,023
-2,327
| -5% | -$101K | ﹤0.01% | 3215 |
|
|
2020
Q3 | $1.4M | Buy |
43,350
+4,833
| +13% | +$189K | ﹤0.01% | 3230 |
|
|
2020
Q2 | $1.7M | Buy |
38,517
+23,905
| +164% | +$1.12M | ﹤0.01% | 3122 |
|
|
2020
Q1 | $479K | Buy |
14,612
+815
| +6% | +$37.5K | ﹤0.01% | 3465 |
|
|
2019
Q4 | $705K | Buy |
13,797
+1,286
| +10% | +$53.9K | ﹤0.01% | 3492 |
|
|
2019
Q3 | $461K | Sell |
12,511
-8,833
| -41% | -$476K | ﹤0.01% | 3560 |
|
|
2019
Q2 | $1.18M | Sell |
21,344
-740
| -3% | -$46.2K | ﹤0.01% | 3304 |
|
|
2019
Q1 | $1.34M | Buy |
22,084
+1,785
| +9% | +$115K | ﹤0.01% | 3264 |
|
|
2018
Q4 | $1.2M | Buy |
20,299
+2,215
| +12% | +$163K | ﹤0.01% | 3304 |
|
|
2018
Q3 | $1.46M | Buy |
18,084
+765
| +4% | +$60.6K | ﹤0.01% | 3358 |
|
|
2018
Q2 | $1.52M | Buy |
17,319
+13,912
| +408% | +$2.44M | ﹤0.01% | 3333 |
|
|
2018
Q1 | $659K | Buy |
3,407
+1,623
| +91% | +$303K | ﹤0.01% | 3498 |
|
|
2017
Q4 | $183K | Buy |
+1,784
| New | +$91K | ﹤0.01% | 3841 |
|
|
2015
Q3 | – | Sell |
-58
| Closed | -$128K | – | 4312 |
|
|
2015
Q2 | $128K | Sell |
58
-18
| -24% | -$36.1K | ﹤0.01% | 3890 |
|
|
2015
Q1 | $177K | Sell |
76
-3
| -4% | -$6.2K | ﹤0.01% | 3904 |
|
|
2014
Q4 | $163K | Buy |
79
+2
| +3% | +$3.85K | ﹤0.01% | 3867 |
|
|
2014
Q3 | $153K | Sell |
77
-294
| -79% | -$727K | ﹤0.01% | 3918 |
|
|
2014
Q2 | $1.32M | Sell |
371
-79
| -18% | -$258K | ﹤0.01% | 3292 |
|
|
2014
Q1 | $1.68M | Sell |
450
-45
| -9% | -$167K | ﹤0.01% | 3219 |
|
|
2013
Q4 | $1.62M | Buy |
495
+10
| +2% | +$39.4K | ﹤0.01% | 3247 |
|
|
2013
Q3 | $2.03M | Sell |
485
-5
| -1% | -$20.1K | ﹤0.01% | 3092 |
|
|
2013
Q2 | $1.65M | Buy |
+490
| New | +$1.86M | ﹤0.01% | 3092 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
Northern Trust's GYRE Position: Q1 2026 in Review
Northern Trust increased its Gyre Therapeutics (GYRE) stake by 3.9% in Q1 2026, buying an estimated $38.7K and bringing the position to 133,841 shares worth $933K. The position accounts for ﹤0.01% of the portfolio, ranked #3373.
Northern Trust first reported a position in GYRE in Q2 2013 and has held it in 43 quarters since. The position peaked at $2.03M in Q3 2013. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- Northern Trust held 133,841 shares of Gyre Therapeutics worth $933K as of Q1 2026.
- Northern Trust bought 4,986 Gyre Therapeutics shares in Q1 2026, an estimated $38.7K.
- Gyre Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3373 holding.
- Northern Trust first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 43 quarters since.
- Northern Trust's Gyre Therapeutics position peaked at $2.03M in Q3 2013.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.